Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About Acolyte

Provider of diagnostic systems for clinical microbiology. The company provides systems based on the bioluminescent detection of adenylate kinase, designed to enable the microbial detection and antibiotic sensitivity determination in hours instead of days, thereby reducing costs and hospital-acquired infections. [Keywords: methicillin-resistant staphylococcus aureus (MRSA)]

Headquarters Location

Building 227

Salisbury, SP4 0JQ,

United Kingdom

44 1980 551320

Missing: Acolyte's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Acolyte's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Acolyte Frequently Asked Questions (FAQ)

  • When was Acolyte founded?

    Acolyte was founded in 2000.

  • Where is Acolyte's headquarters?

    Acolyte's headquarters is located at Building 227, Salisbury.

  • What is Acolyte's latest funding round?

    Acolyte's latest funding round is Acquired.

  • How much did Acolyte raise?

    Acolyte raised a total of $13.46M.

  • Who are the investors of Acolyte?

    Investors of Acolyte include Porton Capital, ANGLE Technology Ventures and Original Investments.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.